RecruitingPhase 3NCT06617897
Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
Studying Rare hemorrhagic disorder due to a constitutional coagulation factors defect
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CSL Behring
- Principal Investigator
- Study DirectorCSL Behring
- Intervention
- CSL511 Fibrinogen concentrate (human)(biological)
- Enrollment
- 90 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06617897 on ClinicalTrials.gov